IGC Pharma Provides New York Location for Alzheimer’s Analysis
IGC Pharma has expanded its CALMA Part II medical trial with Integrative Medical Trials, primarily based in Brooklyn, New York, USA, as a brand new website evaluating IGC-AD1 for agitation related to Alzheimer’s illness.
Integrative Medical Trials conducts research on a variety of central nervous system (CNS) issues, together with gentle cognitive impairment and Alzheimer’s illness.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
The positioning is led by principal investigator Dr. Inna Yuryev-Golger, who has greater than a decade of medical analysis expertise, and Bella Yevseva, who serves as medical trial coordinator.
The middle improves IGC Pharma’s entry to a various affected person inhabitants in a significant metropolitan space. The corporate said that securing websites with CNS expertise is essential to supporting enrollment and affected person engagement within the ongoing examine.
IGC-AD1 is a cannabinoid-based investigational remedy being investigated in a double-blind, placebo-controlled, randomized section II medical trial for sufferers experiencing agitation associated to Alzheimer’s illness.
The continued growth of the CALMA examine demonstrates IGC Pharma’s efforts to facilitate affected person enrollment and guarantee complete medical monitoring all through the examine.
IGC develops therapies for Alzheimer’s illness and metabolic issues utilizing AI. The pipeline consists of TGR-63 (concentrating on amyloid plaques), IGC-AD1 and extra early-stage packages concentrating on tau proteins, metabolic dysfunctions and neurodegeneration.
IGC CEO Ram Mukunda mentioned: “Including Integrative Medical Trials additional strengthens our CALMA medical community with a website with deep experience in CNS issues.
“Their expertise in neuropsychiatric and neurodegenerative analysis helps our dedication to high-quality information technology and environment friendly trial execution as we advance IGC-AD1.”
In 2024, IGC Pharma reported the enrollment of two topics at Neurostudies, a medical trial website in Port Charlotte, Florida, USA, for the Part II trial of IGC-AD1 to deal with agitation in Alzheimer’s illness.
